Kilter Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kilter Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$331	–	1586
2026 Q1	$331	Buy	+1	New	+$340	﹤0.01%	1425

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kilter Group's ALNY Position: Q2 2026 in Review

Kilter Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1 share — an estimated $331 sold.

Kilter Group first reported a position in ALNY in Q1 2026 and held it in 1 quarter. The position peaked at $331 in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Kilter Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Kilter Group sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $331.
Kilter Group first reported a position in Alnylam Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Kilter Group's Alnylam Pharmaceuticals position peaked at $331 in Q1 2026.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.